Heron Therapeutics, Inc.HRTXNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank71
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-11.54%
↑ 99% vs avg
Percentile
P71
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-1499.17%
Historical baseline
PeriodValueYoY Change
2025-11.54%-229.4%
2024-3.50%+95.7%
2023-81.70%+50.2%
2022-164.07%+34.2%
2021-249.29%+0.7%
2020-251.05%-82.1%
2019-137.86%+38.8%
2018-225.44%+63.9%
2017-624.10%+95.3%
2016-13243.16%-